ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LLY vs UNH // RETURN ON INVESTED CAPITAL (ROIC)

Eli Lilly and Company (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: LLY 9 — UNH 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LLY VS. UNH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LLY UNH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 83.64% 88.57% -4.93 UNH /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE 32.36% 11.47% +20.89 LLY /roic <GO>
EV/EBITDA & P/E Valuation 36.4x 16.4x +19.97 UNH /valuation <GO>
Free Cash Flow Yield 2.30% 6.48% -4.18 UNH /fcf-yield <GO>
Operating Margin 40.21% 4.82% +35.39 LLY /operating-margins <GO>
Net Profit Margin 31.90% 3.14% +28.76 LLY /net-margins <GO>
Revenue Growth (YoY) 45.51% 6.46% +39.05 LLY /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.49% 2.28% -1.79 UNH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 9.29 3.12 +6.17 LLY /balance-sheet <GO>
Piotroski F-Score Quality 9/9 7/9 +2.00 LLY /piotroski-score <GO>
Options Implied Move & Put/Call Skew 6.77% 6.74% +0.03 UNH /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 66.6 59.2 +7.40 LLY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.51 0.33 +0.18 LLY /macro-sensitivity <GO>
Forward P/E Multiple 30.6x 17.7x +12.88 UNH /forward-pe <GO>
Enterprise Scale & Market Cap $1.29T $368.83B $924.31B LLY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LLY REV UNH REV LLY GROSS % UNH GROSS % LLY FCF UNH FCF
FY 2025 $65.18B $447.57B 83.0% 88.7% $16.81B $16.07B
FY 2024 $45.04B $400.28B 81.3% 88.3% $8.82B $20.70B
FY 2023 $34.12B $371.62B 79.3% 89.6% $4.24B $25.68B
FY 2022 $28.54B $324.16B 76.8% 89.6% $7.59B $23.40B
FY 2021 $28.32B $287.60B 74.2% 89.2% $7.37B $19.89B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LLY // BETA 0.51
UNH // BETA 0.33